EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Hypertrophic cardiomyopathy dysfunction mimicked in human engineered heart tissue and improved by sodium–glucose cotransporter 2 inhibitors

Paul J M Wijnker iD, Rafeeh Dinani, Nico C van der Laan, Sila Algül, Bjorn C Knollmann, Arie O Verkerk iD, Carol Ann Remme, Coert J Zuurbier, Diederik W D Kuster, Jolanda van der Velden iD

Cardiovascular Research · 2024

DOI: 10.1093/cvr/cvae004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiovascular Research, 2024. Verfasst von Paul J M Wijnker und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Induced Pluripotent Stem Cells, Cardiomyopathy, Hypertrophic, Benzhydryl Compounds, Glucosides. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Netherlands Cardiovascular Research Initiative, Dutch Heart Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiomyopathy, often caused by pathogenic sarcomere mutations. Early characteristics of HCM are diastolic dysfunction and hypercontractility. Treatment to prevent mutation-induced cardiac dysfunction is lacking. Sodium–glucose cotransporter 2 inhibitors (SGLT2i) are a group of antidiabetic drugs that recently showed beneficial cardiovascular outcomes in patients with acquired forms of heart failure. We here studied if SGLT2i represent a potential therapy to correct cardiomyocyte dysfunction induced by an HCM sarcomere mutation. Methods and results Contractility was measured of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) harbouring an HCM mutation cultured in 2D and in 3D engineered heart tissue (EHT). Mutations in the gene encoding β-myosin heavy chain (MYH7-R403Q) or cardiac troponin T (TNNT2-R92Q) were investigated. In 2D, intracellular [Ca2+], action potential and ion currents were determined. HCM mutations in hiPSC-CMs impaired relaxation or increased force, mimicking early features observed in human HCM. SGLT2i enhance the relaxation of hiPSC-CMs, to a larger extent in HCM compared to control hiPSC-CMs. Moreover, SGLT2i-effects on relaxation in R403Q EHT increased with culture duration, i.e. hiPSC-CMs maturation. Canagliflozin’s effects on relaxation were more pronounced than empagliflozin and dapagliflozin. SGLT2i acutely altered Ca2+ handling in HCM hiPSC-CMs. Analyses of SGLT2i-mediated mechanisms that may underlie enhanced relaxation in mutant hiPSC-CMs excluded SGLT2, Na+/H+ exchanger, peak and late Nav1.5 currents, and L-type Ca2+ current, but indicate an important role for the Na+/Ca2+ exchanger. Indeed, electrophysiological measurements in mutant hiPSC-CM indicate that SGLT2i altered Na+/Ca2+ exchange current.

Conclusion

SGLT2i (canagliflozin > dapagliflozin > empagliflozin) acutely enhance relaxation in human EHT, especially in HCM and upon prolonged culture. SGLT2i may represent a potential therapy to correct early cardiac dysfunction in HCM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Induced Pluripotent Stem CellsCardiomyopathy, HypertrophicBenzhydryl CompoundsGlucosidesHumansCanagliflozinCalciumMyocytes, CardiacTroponin TSodiumGlucose

Stichwörter der Autor:innen

Ca2+ handlingContractilityEngineered heart tissueHuman induced pluripotent stem cell-derived cardiomyocytesHypertrophic cardiomyopathySodium–glucose cotransporter 2 inhibitors

Substanzen

empagliflozindapagliflozinCanagliflozinCalciumTroponin TSodiumGlucoseBenzhydryl CompoundsGlucosides

Autor:innen und Institutionen

  • Department of Physiology, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
  • Amsterdam Cardiovascular Sciences, Heart Failure & Arrhythmias, De Boelelaan 1108, 1081 HZ Amsterdam, The Netherlands.
  • Vanderbilt Center for Arrhythmia Research and Therapeutics, Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Experimental Cardiology, Amsterdam UMC, Academic Medical Centre, Amsterdam, The Netherlands.
  • Laboratory for Experimental Intensive Care and Anesthesiology (L.E.I.C.A.), Department of Anesthesiology, Amsterdam UMC, Academic Medical Centre, Amsterdam, The Netherlands.

ORCID-Profile: Paul J M Wijnker, Arie O Verkerk, Jolanda van der Velden

Förderung

  • Netherlands Cardiovascular Research Initiative
  • Dutch Heart Foundation

Zitieren

APA

Wijnker, P. J. M., Dinani, R., van der Laan, N. C., Algül, S., Knollmann, B. C., Verkerk, A. O., Remme, C. A., Zuurbier, C. J., Kuster, D. W. D., & van der Velden, J. (2024). Hypertrophic cardiomyopathy dysfunction mimicked in human engineered heart tissue and improved by sodium–glucose cotransporter 2 inhibitors. Cardiovascular Research. https://doi.org/10.1093/cvr/cvae004

Vancouver

Wijnker PJM, Dinani R, van der Laan NC, Algül S, Knollmann BC, Verkerk AO, et al. Hypertrophic cardiomyopathy dysfunction mimicked in human engineered heart tissue and improved by sodium–glucose cotransporter 2 inhibitors. Cardiovascular Research. 2024. doi:10.1093/cvr/cvae004

BibTeX
@article{Wijnker2024,
  author = {Wijnker, Paul J M and Dinani, Rafeeh and van der Laan, Nico C and Algül, Sila and Knollmann, Bjorn C and Verkerk, Arie O and Remme, Carol Ann and Zuurbier, Coert J and Kuster, Diederik W D and van der Velden, Jolanda},
  title = {Hypertrophic cardiomyopathy dysfunction mimicked in human engineered heart tissue and improved by sodium–glucose cotransporter 2 inhibitors},
  journal = {Cardiovascular Research},
  year = {2024},
  doi = {10.1093/cvr/cvae004}
}
Kostenlos starten →